Skip to main content

Surgical Site Infections

1
Pipeline Programs
2
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Dr. Reddy's Laboratories
1 program
1
DFA-02 Antibiotic GelPhase 21 trial
Active Trials
NCT01888367Completed445Est. Feb 2015
Ondine Biomedical
Ondine BiomedicalBC - Vancouver
3 programs
Nasal antimicrobial photodisinfection therapyN/A1 trial
methylene blue 0.01%/chlorhexidine gluconate 0.25% + light activationPHASE_21 trial
nasal antimicrobial photodisinfection therapyPHASE_31 trial
Active Trials
NCT07189858Active Not Recruiting4,740Est. May 2026
NCT05090657Completed322Est. Aug 2022
NCT06702878Active Not Recruiting4,514Est. May 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Ondine Biomedicalnasal antimicrobial photodisinfection therapy
Ondine Biomedicalmethylene blue 0.01%/chlorhexidine gluconate 0.25% + light activation
Dr. Reddy's LaboratoriesDFA-02 Antibiotic Gel
Ondine BiomedicalNasal antimicrobial photodisinfection therapy

Clinical Trials (4)

Total enrollment: 10,021 patients across 4 trials

NCT06702878Ondine Biomedicalnasal antimicrobial photodisinfection therapy

Light-Activated Antimicrobial Therapy to Prevent Surgical Site Infections

Start: Dec 2024Est. completion: May 20264,514 patients
Phase 3Active Not Recruiting
NCT05090657Ondine Biomedicalmethylene blue 0.01%/chlorhexidine gluconate 0.25% + light activation

Nasal Photodisinfection in All Patients Presenting for Surgery for a Wide Range of Surgical Procedures

Start: Feb 2022Est. completion: Aug 2022322 patients
Phase 2Completed
NCT01888367Dr. Reddy's LaboratoriesDFA-02 Antibiotic Gel

Safety, Efficacy and Tolerability Study of up to 20 mL of DFA-02 in Patients Undergoing Abdominal Surgery

Start: Oct 2013Est. completion: Feb 2015445 patients
Phase 2Completed
NCT07189858Ondine BiomedicalNasal antimicrobial photodisinfection therapy

Light-Activated Antimicrobial Therapy to Prevent Surgical Site Infections - Canada

Start: Jan 2026Est. completion: May 20264,740 patients
N/AActive Not Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.